Discussion about this post

User's avatar
The AI Architect's avatar

Incredibly thorough investigation here. The timing gap between vaccination and death being under 2 weeks for most cases is somethign regulators typically flag for closer review, yet somehow only 2 out of 160 cases got escalated. I ran into similar reporting blind spots when looking at pharmacovigilance data across different countries and the patterns were pretty consistent tbh. The real question is whether institutional capture makes meaningful post-market surveillance impossible or if its just resource constraints.

No posts

Ready for more?